£1 million award to push forward regenerative medicine research

13 Dec 2018, 10:19 a.m.

Sterile GOSgene laboratory

Researchers at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH) are to lead a new collaboration exploring how stem cells can be engineered to evade immune responses. They will apply the latest genome editing technologies to modify ‘pluripotent stem cells’ – cells that can go on to become almost any cell in the body and could eventually be used to repair and regenerate diseased organs. There are around 6400 people waiting for organ transplants in the UK, and these new techniques may help some of them while they wait for suitable donors.

The project has been awarded a prestigious £1 million grant from the Medical Research Council (MRC) and is led by National Institute for Health Research (NIHR) GOSH Biomedical Research Centre investigators,  Waseem Qasim and Paolo De Coppi, both NIHR Professors at ICH and consultants at GOSH, as part of a collaborative network involving clinicians and scientists from regenerative medicine hubs across the UK.

The 3-year project aims to efficiently and safely test manufacture of 'universal cells' using cutting-edge CRISPR-Cas9 genome editing tools to make precise changes to the cells' DNA and disrupt ‘flags’ om the cell's surface called Human Leukocyte Antigens (HLAs). These flags are how the immune system usually distinguishes between ‘self’ and ‘non-self’ tissue and the project aims to deliver 'universal' cells that can evade immune rejection. State of the art sequencing and computer modelling will be used to assess the efficiency of the editing process and screen for unwanted effects.

This new application of genome editing technology builds on strategies where immune cells are engineered to fight certain types of childhood cancer, and is part of wider initiatives to bring new types of treatments to NHS patients.

Young people donate tissue samples to unlock mysteries of arthritis

A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.

Toddler doing well after receiving newest gene therapy available on NHS

A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.

Genes may help to predict which children will respond well to arthritis treatment

A team of researchers at Great Ormond Street Hospital (GOSH) and University College London (UCL) have identified a set of genes that could be used to help doctors predict which children will respond well to treatment for juvenile idiopathic arthritis.

Making it easier to invest in frontline care

GOSH and UCL have signed a landmark agreement to simplify the commercialisation of any joint research and innovation and ensure any financial proceeds are shared equally.